New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
Heart failure with reduced ejection fraction (HFrEF) is a public health issue, because some patients, despite using standard treatment, still develop worsening heart failure. The risk of adverse outcomes is especially high in patients who require readmission or emergency care on an outpatient basis....
Saved in:
| Main Author: | I. V. Gribkova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2024-03-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2954 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings
by: Maria del Carmen Asensio-Lopez, et al.
Published: (2025-04-01) -
Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States
by: Stephen J. Greene, et al.
Published: (2025-08-01) -
Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction
by: V. I. Podzolkov, et al.
Published: (2023-10-01) -
Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
by: E. F. Muslimova, et al.
Published: (2025-01-01) -
Predictors of sustained reverse remodelling in patients with heart failure with reduced ejection fraction
by: Silas Ramos Furquim, et al.
Published: (2025-06-01)